Complain about a product or service

Cancer Painkiller Can Be Fatal, Manufacturer Warns

Fentora linnked to several deaths among cancer patients

September 14, 2007

Cancer • Complementary Methods Used to Deal With Cancer • Researchers Report Cancer Breakthrough • Great Lakes Region A Potential Graveyard • Oral Sex Can Cause Cancer in Men • New Cancer Drug May Be On the Way • Thinking Positive Does Little To Help Cancer Survival • FDA Issues Warning about Fentora • Cancer Painkiller Can Be Fatal, Manufacturer Warns • A Gene That “Turns Off” Cancer? • Key to Reducing Cancer Risk Not a Mystery • Researchers Study NSAIDs and Cancer • Vitamin D May Protect Against Some Cancer • Report Tracks Decline In Cancer Deaths • Popular Cancer Drug Called "Toxic" To Heart • Colorectal Cancer Risk Higher for Smokers, Drinkers and Men • Health Groups Dispute Low Fat Study Findings • Research: Veggies May Protect Against Cancer • Total Cancer Deaths Down This Year • Circumcision May Protect Against Cervical Cancer • Study: Low-Fat Diet Does Little to Reduce Breast Cancer Risk • Study Finds Teflon Chemical In Newborns' Umbilical Cords • Study: Omega-3 Consumption Not Linked to Reduced Risk of Cancer • Canine Cancer Detectors • Is Lung Cancer Becoming a Woman's Disease? • Prostate Cancer Genes Identified

Drugmaker Cephalon has sent letters to doctors warning of serious risks with its drug Fentora, a painkiller often prescribed for cancer patients.

The letter warns doctors to carefully follow dosage guidelines after a number of deaths among patients taking the drug. The letter was issued in collaboration with the U.S. Food and Drug Administration

The company said those suffering from the reactions, including death, either took the drug improperly or weren’t candidates for it in the first place.

The letter has been sent to physicians, pharmacists, managed care organizations, and other healthcare professionals and it emphasizes the need to adhere to the Fentora prescribing information, including the following:

• Fentora is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

• Fentora must only be prescribed to patients who are routinely taking around-the-clock opioids. Fentora should not be prescribed to patients for acute pain, postoperative pain, headache/migraine, or sports injuries.

• Only one tablet per episode should be taken once a dose is established and patients must wait at least four hours before taking another dose of FENTORA.

• Fentora is not bioequivalent to or a generic version of ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]; therefore, Fentora should not be substituted for ACTIQ or any other fentanyl-containing pain medication.

• Cephalon said it is working with the FDA to emphasize the appropriate patient selection, dosing and administration in the Fentora label and Risk Minimization Action Plan.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.